Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for Izalontamab Brengitecan (iza-bren) for the Second-line Treatment of EGFR-TKI-resistant and EGFR-mutated Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 ·

On 6ix: 6ix.com/news/688506sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-acceptance-of-the-marketing-application-for-izalontamab-brengitecan-iza-bren-for-the-second-line-treatment-of-egfr-tki-resistant-and-egfr-mutated-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer

Announcement on Voluntary Disclosure of Acceptance of the Marketing Application for Izalontamab Brengitecan (iza-bren) for the Second-line Treatment of EGFR-TKI-resistant and EGFR-mutated Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases